TIETOJA TÄSTÄ PODCASTISTA 🔗

Päivitä taajuus:
every 21 days
Keskimääräinen äänen pituus:
9 minutes
Vierashaastattelut
Englanti
Yhdysvallat
213 jaksoa
vuodesta 2. elokuuta 2017
episodic

VIIMEISIN JAKSO 🔗

Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.

HAE EDELLISIÄ EPISODEJA

Hae kanavan Talking Points vanhoja jaksoja.

EDELLISET JAKSOT

The FAME 3 Trial

William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.

The PRAGUE-25 Study

Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.

The BETAMI-DANBLOCK Trial

How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.

The PROCTOR Trial

Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.

The SELUTION DeNovo Trial

Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.

The VESALIUS-CV Trial

Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.

The META-AF Trial

Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
Vastuuvapautusilmoitus: Tälle sivulle upotettu podcast ja kuvitus ovat peräisin TCTMD:ltä, joka on sen omistajan omaisuutta, eikä se ole sidoksissa Listen Notes, Inc:n tukemaan.